| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
19,768 |
11,467 |
$535K |
| 87481 |
|
10,419 |
8,556 |
$113K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,584 |
2,327 |
$41K |
| 87631 |
|
2,637 |
2,203 |
$40K |
| 87653 |
|
12,673 |
10,343 |
$39K |
| 87641 |
|
10,349 |
8,502 |
$32K |
| 87500 |
|
10,063 |
8,446 |
$31K |
| 87529 |
|
3,742 |
3,139 |
$27K |
| 87640 |
|
7,919 |
6,453 |
$17K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
3,676 |
3,107 |
$16K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
4,773 |
3,930 |
$14K |
| 87625 |
|
3,267 |
2,725 |
$13K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,586 |
2,171 |
$12K |
| 87511 |
|
3,286 |
2,711 |
$9K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
2,222 |
1,867 |
$9K |
| 87486 |
|
3,131 |
2,531 |
$9K |
| 87541 |
|
3,087 |
2,491 |
$8K |
| 87581 |
|
3,088 |
2,491 |
$8K |
| 87561 |
|
2,448 |
1,956 |
$7K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
3,550 |
1,506 |
$7K |
| 87563 |
|
2,387 |
2,003 |
$6K |
| 81514 |
|
34 |
32 |
$5K |
| 87556 |
|
1,470 |
1,220 |
$4K |
| 87493 |
|
1,393 |
1,210 |
$4K |
| 81226 |
|
718 |
559 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
505 |
444 |
$3K |
| 81225 |
|
699 |
540 |
$2K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
569 |
479 |
$2K |
| 81231 |
|
625 |
487 |
$2K |
| 81230 |
|
399 |
303 |
$1K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
542 |
445 |
$1K |
| 81479 |
Unlisted molecular pathology procedure |
786 |
266 |
$974.23 |
| 81227 |
|
631 |
492 |
$820.50 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
703 |
380 |
$685.64 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
184 |
154 |
$436.86 |
| 81291 |
|
385 |
291 |
$427.23 |
| 81328 |
|
228 |
200 |
$400.67 |
| 81241 |
|
136 |
118 |
$226.21 |
| 87471 |
|
192 |
148 |
$205.69 |
| 81240 |
|
136 |
118 |
$193.59 |
| 81401 |
|
102 |
92 |
$109.93 |
| 81355 |
|
128 |
116 |
$70.77 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
64 |
33 |
$66.87 |
| 87505 |
|
18 |
13 |
$0.00 |